Toludesvenlafaxine extended release - Luye Pharma
Alternative Names: 4-Methylbenzoate desvenlafaxine hydrochloride; Anshufaxine hydrochloride extended release - Luye pharma; Ansofaxine hydrochloride extended release - Luye Pharma; Desvenlafaxine prodrug; LPM-570065; LY-03005; Ruoxinlin; Toludesvenlafaxine hydrochloride extended release - Luye Pharma; Toludesvenlafaxine hydrochloride sustained-release - Luye PharmaLatest Information Update: 08 Sep 2025
At a glance
- Originator Luye Pharma Group
- Class Antidepressants; Anxiolytics; Benzoates; Cyclohexanols; Small molecules
- Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Major depressive disorder
- Phase III Generalised anxiety disorder
Most Recent Events
- 18 Aug 2025 Luye Pharma plans to submit marketing authorisation application for Generalised anxiety disorder in China (PO, Controlled release), by the end of 2025
- 18 Aug 2025 Luye Pharma Group completes enrolment in phase III clinical trial in Generalised anxiety disorder in China (PO) (NCT05970510)
- 07 Apr 2025 Registered for Major depressive disorder in Macau (PO)